Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1998-03-03
2000-04-25
Dees, Jose' G.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
534 10, 534 14, 556 13, 556 18, A61K 5104, C07F 500, C07F 900
Patent
active
060541156
ABSTRACT:
A compound and method of making a compound for use as a diagnostic or therapeutic pharmaceutical comprises at least one functionalized hydroxyalkyl phosphine donor group and one or more sulfur or nitrogen donor and a metal combined with the ligand.
REFERENCES:
patent: 4419339 (1983-12-01), Neirinckx
patent: 4439196 (1984-03-01), Higuchi
patent: 4446224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4475196 (1984-10-01), La Zor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4795626 (1989-01-01), Deutsch et al.
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169383 (1992-12-01), Gyory et al.
patent: 5175343 (1992-12-01), Fritzberg et al.
patent: 5225182 (1993-07-01), Sharma
patent: 5635158 (1997-06-01), Mazzi et al.
Beard et al., (1965) The preparation and properties of [Re(amine).sub.4 O.sub.2 ]+ type ions. Inorg. Chem., 4:797-803.
Berning et al., (1996) In vitro and in vivo characterization of a 99mTc complex with tris(hydroxymethyl)phosphine (THP) J. Nucl. Med. Biol., 23:617-622.
Betz et al., (1994) in Basic Neurochem. Molecular Cell, Raven Press Ltd., NY, 5th ed., pp. 681-699.
Blessing (1995) An empirical correction for absorption anisotropy Acta Crystallogr., Sect. A, 51:33-38.
Brem et al. (1993) Polymers as controlled drug delivery devised for the treatment of malignant brain tumors. Eur. J. Pharm. Biopharm., 39:2-7.
Clarke and Podbielski (1987) Medical diagnostic imaging with complexes of 99mTc. Coord. Chem. Rev., 78:253-331.
DeRosch et al., (1992) Kit development for the Tc-99m myocardial imaging agent. J. Nucl. Med., 33:850.
Greenwood and Earnshaw, (1993) in Chemistry of the elements, Pergamon Press, New York, Chapter 12, pp. 546-636.
Higley et al. (1993) Technetium-99m-1,2bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution . . . J. Nucl. Med., 34:30-38.
Hnatowich, (1990) Antibody radiolabeling, problems and promises. Nucl. Med. Biol., 17:49-55.
Ichimura et al., (1984) Technetium electrochemistry. 2. Electrochemical and spectroelectrochemical studies . . . Inorg. Chem., 23:1272-1278.
Jain et al., (1993) Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent . . . J. Nucl. Med., 34:1254-1259.
Katti (1996) Recent advances in the chemistry of water-soluble phosphines--catalytic and biomedical aspects. Current Science, 70:219-225.
Katti et al., (1995) Coordination chemistry of phosphorus (III) and phosphorus(V) hydrazides. Chem. Soc.Rev., 97-107.
Libson et al., (1983) Synthesis, characterization, and electrochemical properties of tertiary diphosphine . . . Inorg. Chem., 22(12), 1695-1704.
Marmion et al., (1995) in Technetium and Rhenium in Chemistry and Nuclear Medicine--4; Nicolini, M et al. eds; Servizi Grafici Editoriali, Padova, pp. 253-258. [not available].
Mayer and Kaska, (1994) Sterochemical control of transition metal complexes by polyphosphine ligands. Chem. Rev., 94:1239-1272.
Muna et al., (1994) Synthesis, radiochemical and biological evaluation of 99mTc[N4 (O) Phe]-octreotide . . . J. Nucl. Bio. Med., 38:452. [not available].
Orpen et al., (Harrison et al.) (1989) Water soluble, zero-valent, platinum-, palladium-, and nickel . . . Chem. Soc. Chem. Commun., 1096-1097.
Pardridge (1992) Blood-brain barrier and new approaches to brain drug delivery. West J. Med., 156(3)281-286.
Pardridge (1992) Recent developments in peptide drug delivery to the brain. Pharm. Toxicol., 71(1)3-10.
Pardridge [Bickel et al.](1993) Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA, 90(7)2618-2622.
Reddy et al., (1996) Synthesis and characterization of dioxorhenium complexes derived from water-soluble diphosphine . . . J. Chem. Soc., Dalton Trans., 4459-4462.
Reddy et al., (1996) Hydroxymethyl bis(phosphines) and their palladium (II) and platinum (II) complexes . . . J. Chem. Soc., Dalton Trans., pp. 1301-1304.
Reddy et al., (1996) Chemistry in environmentally benign media. Synthesis and characterization of rhenium (V) . . . Inorg. Chem., 35:1753-1757.
Reddy et al., (1995) Chemistry in environmentally benign media Part 1. Synthesis and characterization . . . Inorg. Chim. Acta., 240:367-370.
Refosco et al., (1993) Co-ordination of (o-aminophenyl)diphenyl-phosphine in complexes . . . J. Chem. Soc. Dalton Trans., 605-618.
Sheldrick (1993) Program for crystal structure refinement. University of Gottingen, Germany [n/available].
Sheldrick (1990) Phase annealing in SHELX-90: direct methods for larger structures. Acta Crystallogr., A46:467.
Smith et al., (1996) New advances in the synthesis of water-soluble triphosphine and the development of tripodally . . . J. Chem. Soc. Chem. Commun., 2557-2558.
Tisato et al., (1995) Syntheses and structural characterizations of six-coordinatoe Oxo-M(V) complexes . . . Inorg. Chem., 34:1779-1787.
Vanderheyden et al., (1985) Comparison of the chemical and biological properties . . . Inorg. Chem., 24:1666-1673.
Vanderheyden et al. (1984) Synthesis and characterization of cationic technetium complexes of 1,2-Bis(dimethylphosphino)ethane . . . Inorg. Chem., 23:3184-3191.
CHatt et al., Rhodium(i), Palladium(ii), an dPlatinum(ii) Complexes containing Ligands of the Type PRnQ3-n (n=0,1, or 2; R=Me, Et, But, or Ph; Q-CH2OCOMe or CH2OH), J. Chem. Soc., p. 2021-2028, 1973.
Abrams et al., "Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide . . . " J Nucl Med 31:2022-2028, (1990).
Abrams et al. "Synthesis and crystal and molecular structure of a technetium-hydralazino complex . . . " Inorg Chim Acta 173:133-135, (1990).
Chianelli et al. "99mTc-interleukin-2: a new radiopharmaceutical for the in vivo detection of lymphocytic infiltration" J Nucl Biol Med 38:476, (1994).
Deutsch, "Aspects of the chemistry of technetium phosphine complexes" Radiochim Acta 63:195-197, (1993).
Ellis et al., "Water-soluble tris(hydroxymethyl) phosphine complexes with nickel, palladim and platinum . . . " Inorg Chem 31:3026-3033, (1992).
Fritzberg et al., "Specific and stable labeling of antibodies with 99mTc with a dimide dithiolate chelating agent" Proc. Natl. Acad. Sci., USA 85:4025-4029, (1988).
Gustavson et al., "Synthesis of a new class of Tc-chelating agents . . . " Tetrahedron Lett, vol. 32, No. 40, pp. 5485-5488 (1991).
Jurisson et al., "Coordination compounds in nuclear medicine" Chem Rev 93:1137-1156, (1993).
Kelly et al., Technetium-99m-Tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging J Nucl Med 34:222-227 (1993).
Knight et al., "Thrombus imaging with 99mTc synthetic peptides based upon the binding domain of a monoclonal antibody . . . " J Nucl Med 35:282-288, (1994).
Lister-James et al., "A structure-activity-relationship (SAR) study of somatostatin receptor-binding peptides . . . " J Nucl Med, 35:257-258P, (1994).
Marmion et al., "Radiopharmaceutical development of TechneScan Q-12" J Nucl Biol Med 38:455-456, (1994).
Meares et al., "Chelate radiochemistry: cleavable linkers lead to altered levels of radioactivity in the liver" Int J Cancer 2:99-102, (1988).
Maina et al., "Synthesis, radiochemical and biological evaluation of 99mTc[N4 (O) Phe]-octreotide . . . " J Nucl Bio Med 38:452, (1994).
Nock et al., "99mTc-N4-Lys-Biotin, a new biotin derivative useful for pretargeted avidin-biotin immunoscintigraphy . . . " J Nucl Biol Med 38:460, (1994).
Nowotnik and Nunn, "Technetium SPECT agents for imaging heart and brain" DN and P 5:174-183, (1992).
Parker, "Tumour targeting with radiolabeled macrocycle-antibody conjugates" Chem. Soc. Rev. 19:271-291, (1990).
Pasqualini et al., "Bis(dithiocarbamato)nitrido technetium-99m radid-pharmaceuticals: a class of neutral myocardial . . . " J. Nucl. Med. 35: 334-340 (1994).
Rao et al., "Kinetics and mechanism of reactions of S-protected dithiol monoaminemonoamide (MAMA) ligands with technetium" Nucl Med Biol, 19:889-895, (1992).
Troutner, "Chemical and physical properties of radionuclides" Nucl Med Biol 14:171 (1987).
Volkert et al., "Therapeutic radionuclides: production and decay prop
Berning Douglas E.
Karra Srinivasa Rao
Katti Kattesh V.
Ketring Alan R.
Smith C. Jeffrey
Dees Jos,e G.
Hartley Michael G.
The Curators of the University of Missouri
LandOfFree
Hydroxymethyl phosphine compounds for use as diagnostic and ther does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxymethyl phosphine compounds for use as diagnostic and ther, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxymethyl phosphine compounds for use as diagnostic and ther will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-991168